Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Cook Islands Tech Reporter.
Press releases published on August 11, 2025
Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025
COPENHAGEN, Denmark, August 11, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its second quarter 2025 financial results …
CervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Reported 32-week data from Phase 2b RewinD-LB Trial Extension phase showing neflamapimod treatment resulted in a substantial reduction in clinically significant worsening compared to control arm over 32 weeks, which improved further among patients who have …
vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin
HIGH POINT, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated …
Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results
- Released positive topline data from the VIRAGE Phase 2b study of VCN-01 (zabilugene almadenorepvec); expanded data to be presented at the European Society for Medical Oncology (ESMO) 2025 Congress in October - - VCN-01 demonstrates potential in …
GBT Technologies Intends to Rebrand as Wertheim & Company; Craig Marshak Appointed CEO; Emil Assentato Joins as Strategic Investor
WEST HOLLYWOOD, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- GBT Technologies Inc. (OTC Pink: GTCH) (“GBT” or the “Company”) today announced its intention to change its corporate name to Wertheim …
4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
4D-150 Phase 3 program in wet AMD advancing ahead of plan, with expected 4FRONT-1 data readout accelerated to H1 2027 from H2 2027 and 4FRONT-2 initiated ahead of schedule Presented positive 60-week results from 4D-150 SPECTRA clinical trial in DME …
Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del segundo trimestre de 2025
- Se han publicado datos preliminares positivos del estudio de Fase 2b de VIRAGE de VCN-01 (zabilugene almadenorepvec); los datos ampliados se presentarán en el Congreso de la European Society for Medical Oncology (ESMO) de 2025 que tendrá lugar en octubre …
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
CONSHOHOCKEN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, Aug. 12, 2025 at 10:30 A.M. EDT. The …
IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed
Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients treated with pembrolizumab monotherapy, HR=0.77 (CI 0.58-1.00), (p=0.056), with median …
Jupiter Neurosciences Introduces Nugevia™ MND: A Cognitive Health Supplement Leveraging Clinically Validated Neuroscience
MND combines proprietary resveratrol-based platform and NovaSOL® Curcumin to enhance cognitive performance and support neuroprotective health Jupiter, Florida, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the " …
Wearable Devices Secures U.S. Patent for Groundbreaking Neural Interface Technology
Granted Patent Covers Neural Measurement of Weight, Torque and Force with Broad Applications in Brain-Computer Interfaces, Industry 4.0 and Extended Reality YOKNEAM ILLIT, ISRAEL, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Wearable Devices Ltd. (the “Company” or “ …
RedCloud Delivers Stellar Year-Over-Year Customer Growth In H1 With Positive Retailer Purchasing Behavior
LONDON, Aug. 11, 2025 (GLOBE NEWSWIRE) -- RedCloud Holdings plc (“RCT”) (“RedCloud” or the “Company”) today announces positive year-over-year customer growth numbers across its markets with a growing appetite for bulk trade between distributors, while …
Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial
TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to innovative therapies for neurodegenerative disorders, …
MediPharm Labs Sets Date to Report Second Quarter 2025 Financial Results
TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will …
Rail Vision Receives European Patent for Innovative Locomotive Imaging Technology
Ra’anana, Israel, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Rail Vision Ltd. (Nasdaq: RVSN) (“Rail Vision” or the “Company”), an early commercialization stage technology company seeking to revolutionize railway safety and the data-related market, today announced …
Altimmune Board of Directors Appoints Jerry Durso as Chairman
Appointment recognizes Mr. Durso’s extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH Mitchel Sayare, Ph.D., to remain on the Board as Independent Director GAITHERSBURG, Md., Aug. 11, 2025 (GLOBE NEWSWIRE) …
Avicanna Announces US Patent and Trademark Office Issuance of New Patent
USPTO Issues Patent No. US 12,343,315 B2 covering topical cannabinoid compositions for clear skin TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on …
Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2025 financial …